Omnipod platform leader in tubeless insulin patch pumps, 10th consecutive year of ≥20% growth, expanding margins and solid FCF, but hit by a severe guidance cut (Type 2 patient attrition in the first 90 days of therapy) that triggered a -16.5%/-21.9% single-day drop on Aug 5, 2026, an early-stage securities class action (lead plaintiff deadline Aug 31, 2026 already passed, case unresolved) and two board resignations. The market is pricing a forward EV/Revenue multiple of ~2.9x versus a historical peak of ~9x and DexCom's 6x: a wide discount, but not unwarranted — the key question is whether the Type 2 retention problem is temporary (fixable) or structural.
QUALITY selection factor (real earnings, expanding margins, established franchise), but scenario weights deliberately shifted toward bear (20/50/30 instead of the 25/50/25 default) given the active, unresolved binary risk from the securities litigation and guidance credibility after the second reset in a year. If the gap between FV and analyst consensus ($171.91) looks wide, it is only +9.5% — within tolerance, explained by the buyback accretion given more weight here than in standard analyst targets. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Omnipod platform (gross EV) | 4.0x EV/Revenue FY26E ($3,277M = FY25 $2,708M ×1.21) = $13,108M EV; /69.35M sh. | +189.02 |
| Net debt (TTM Jun-26) | $948.4M total debt − $534.9M cash = $413.5M; /69.35M sh. | −5.96 |
| Buyback accretion (12M fwd) | ~$300M planned repurchase @ ~$140/sh avg ≈ 2.14M sh retired (−3.1% of the 69.35M float); equity redistributed over the reduced share base | +5.85 |
| Litigation reserve (securities class action) | 40% probability × $120M expected cost/settlement (estimate — no public settlement figure disclosed) /69.35M sh. | −0.69 |
| FV base case | Exact sum of the rows above | ≈ $188.22 |
Short interest remains low despite the active securities class action and guidance cut: it signals that short sellers do not (for now) see an existential risk, consistent with a "temporary setback" read rather than a structural bear thesis — but it's also a data point that can shift quickly if Type 2 retention doesn't improve over the next few quarters.
| Item | FY2023 | FY2024 | FY2025 | Guidance FY2026 |
|---|---|---|---|---|
| Revenue ($M) | ~1,699 (estimated from FY24's stated +22% growth) | 2,072 | 2,708 | ~3,250-3,304 (20-22% cc) |
| Growth YoY | +30% | +22% | +30.7% (29.5% cc) | 20-22% cc (cut from 21-23%) |
| Gross margin | N/A | N/A | 71.6% (+180bps) | N/A |
| Adj. operating margin | N/A | N/A | 17.6% (+270bps) | +~100bps guided |
| Net income GAAP ($M) | N/A | N/A | 247.1 | N/A |
| Adj. net income ($M) | N/A | N/A | 354.4 (+53.8%) | Adj. EPS +≥30% guided |
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 649.0 | 706.0 | 784.0 | 761.7 | 801.7 |
| Gross margin % | N/A | N/A | N/A | N/A | N/A |
| Net income ($M) | N/A | N/A | N/A | N/A | 95.0 |
| End-of-period cash ($M) | N/A | N/A | 716.1 | N/A | 534.9 |
Business model — Omnipod: a diabetes patch pump platform
Revenue today is over 95% concentrated in a single product family (Omnipod), split across two macro geographic segments: US Omnipod (~68% of Q2 2026 revenue, $544.1M, +20.1% YoY) and International Omnipod (accelerating sharply, guidance raised to +30-32% for FY26). The problem that emerged in early August 2026 is specific to the US segment: Type 2 patients — over 40% of new US customer starts — are showing weaker-than-expected utilization and retention in the first 90 days of therapy, prompting management to cut US Omnipod guidance by 3 percentage points while still confirming (and actually raising) EPS guidance on the back of margin expansion.
Legal, regulatory and risk analysis
SWOT analysis
- +Category leader in tubeless patch pumps, 10 consecutive years of ≥20% growth
- +Recurring, consumables-like revenue model, 71.6% gross margin
- +$377.7M FY25 FCF, very low financial leverage
- +Active $475M buyback as a management conviction signal
- −>95% of revenue concentrated in a single product family (Omnipod)
- −Weak Type 2 retention in the first 90 days of therapy — the cause of the guidance cut
- −Two board resignations in the same month as the guidance cut
- →International expansion (30-32% guided), penetration still low
- →The Type 2 segment remains a potentially huge market if the retention problem is solved
- →Multiple re-rating if the market regains trust in guidance (today 2.8x fwd vs. DexCom's 6x)
- !Unresolved securities class action, uncertain cost and outcome
- !Growing competition from Medtronic Simplera and Tandem Mobi
- !Risk that the Type 2 problem is structural rather than an onboarding fix
Summary by assessment area
- Leverage <1x EBITDA, 14.4x interest coverage
- Solid FCF, no refinancing need
- Type 2 retention needs to be fixed within 2-3 quarters
- Concentration in a single product platform
- Early-stage securities class action, outcome/cost uncertain
- Two board departures to monitor, not yet a conclusive pattern
Sources: investor.insulet.com (Q2/Q4 2026 and Q4 2025 releases), stockanalysis.com, macrotrends.net, fintel.io, simplywall.st, AAII, Yahoo Finance, Benzinga, TipRanks, Kessler Topaz / Bleichmar Fonti & Auld / Robbins LLP / Levi & Korsinsky (class action), ad-hoc-news.de (board resignations), stockanalysis.com (DXCM/TNDM/EMBC). Market data as of Sep 15, 2026: PODD ~$131.96 (close Sep 11, 2026), market cap ~$9,152M, 52W: $131.96–$354.88 (new period low set after the early-Aug-2026 sell-off), 69.35M diluted shares. Short interest: 2.82%. Securities class action active, outcome not yet determined. This document is for informational purposes only and does not constitute financial or investment advice.